Last reviewed · How we verify
ASP3550
ASP3550 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
ASP3550 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes.
At a glance
| Generic name | ASP3550 |
|---|---|
| Also known as | Degarelix |
| Sponsor | Astellas Pharma Inc |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, ASP3550 reduces glucose reabsorption in the kidneys, leading to decreased glucose levels in the blood. This mechanism is primarily used to treat type 2 diabetes.
Approved indications
- Treatment of type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery (PHASE2, PHASE3)
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial (PHASE3)
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (PHASE3)
- Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial (PHASE2)
- Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer (PHASE2)
- Study to Find Maintenance Dose for Periodic Administration of ASP3550 (PHASE2)
- A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer (PHASE3)
- Phase II Study of ASP3550 in Patients With Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASP3550 CI brief — competitive landscape report
- ASP3550 updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI